Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vapor Ablation for Localized Cancer Lesions
Sponsor: Uptake Medical Technology, Inc.
Summary
This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment. Patients will be followed for up to 12 months.
Official title: Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-09-01
Completion Date
2028-06-30
Last Updated
2025-02-27
Healthy Volunteers
No
Interventions
Bronchoscopic Thermal Vapor Ablation
Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
Locations (2)
Otto-Wagner Hospital
Vienna, Austria
Azienda Ospedaliero - Universitaria
Ancona, Italy